Mary's Medicinals to Participate in CMS Cannabinoid Therapy Trial

The company's award-winning CBD products will be part of the new federal healthcare program.

Apr. 2, 2026 at 1:33am

Got story updates? Submit your updates here. ›

Mary's Medicinals, a subsidiary of MM Brands Inc., has announced its intent to participate in the newly established Centers for Medicare & Medicaid Services (CMS) cannabinoid therapy trial program. The initiative aims to facilitate access to reliable cannabinoid therapies through established healthcare models, with eligible patients gaining access starting in 2027.

Why it matters

The CMS program represents a significant step forward in the mainstream acceptance and integration of cannabinoid-based medicines, particularly non-intoxicating CBD products. This could pave the way for wider adoption of natural alternatives to traditional pharmaceutical therapies.

The details

Under the new Beneficiary Engagement Incentive (BEI) framework, CMS has established eligibility for products containing up to 3 mg of tetrahydrocannabinols per serving, allowing for the inclusion of full-spectrum hemp-derived CBD products like those offered by Mary's Medicinals. The program will evaluate the impact of cannabinoids on patient outcomes and their potential as alternatives to traditional pharmaceutical therapies.

  • The CMS cannabinoid therapy trial program was launched on April 1, 2026.
  • Eligible patients will have access to the program through the Long-term Enhanced ACO Design (LEAD) model beginning in 2027.

The players

Mary's Medicinals

A subsidiary of MM Brands Inc. and a pioneer in the cannabis industry, known for its "science-first" approach to product development.

Centers for Medicare & Medicaid Services (CMS)

A federal agency that administers the Medicare program and works in partnership with state governments to administer Medicaid.

Joe Bayern

CEO of Mary's Medicinals and MM Brands.

Got photos? Submit your photos here. ›

What they’re saying

“We look forward to working within the CCMI program to provide its participants with access to reliable products that can improve the lives of millions of patients.”

— Joe Bayern, CEO of Mary's Medicinals and MM Brands

“We are confident that the results of this program will create a formal pathway toward natural alternatives to opioids and synthetic prescription drugs.”

— Joe Bayern, CEO of Mary's Medicinals and MM Brands

What’s next

Beginning in 2027, eligible patients will have access to Mary's Medicinals' cannabinoid-based products through the CMS Long-term Enhanced ACO Design (LEAD) model.

The takeaway

The CMS cannabinoid therapy trial program represents a significant milestone in the mainstream acceptance of cannabinoid-based medicines, particularly non-intoxicating CBD products. This could lead to wider adoption of natural alternatives to traditional pharmaceutical therapies and help redefine the perception of cannabinoid-based therapies.